Exelixis Inc at JPMorgan Healthcare Conference Transcript
All right, great. I'm Eric Joseph, one of the senior biotech analysts here at JPMorgan. And our next presenting company is Exelixis Pharmaceuticals. It's my pleasure to welcome CEO, Mike Morrissey, to tell us a little bit about the company.
Just as a reminder, the breakout Q&A for this meeting will be across the hall in the Georgian Room. With that, Mike?
All right. Excellent. Thank you. All right, good afternoon, everybody. Thanks for sticking around late and hearing our story. I'll go through a pretty detailed deck this afternoon.
Before I start, I thought it'd be important to put the last few days and 2020 into context based on where we came in 2019 and before then. Last year, especially, was a year of, I would say, hyper focus on 2 issues: our weekly IMS script numbers every Friday; and then lots of questions about 9ER, the front-line pivotal trial of cabo and nivo versus
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
